Helen Sabzevari serves as the Chief Executive Officer at PRECIGEN INC, a biotechnology company focused on the discovery and development of innovative gene and cell therapies. With a robust background in the biopharmaceutical industry, Sabzevari brings a wealth of experience and expertise to her role at PRECIGEN. She holds a Ph.D. in Immunology from the Medical University of South Carolina and has dedicated her career to advancing the field of immunotherapy and precision medicine. Before joining PRECIGEN, Sabzevari held several high-level positions at notable biotech companies, where she spearheaded numerous successful research and development initiatives. Her work has been instrumental in bringing groundbreaking therapies from the laboratory to the clinic, significantly impacting the treatment landscape for various diseases. At PRECIGEN, Sabzevari leads the company's strategic direction, overseeing the development and commercialization of its proprietary technologies, including the UltraCAR-T platform, which aims to revolutionize cancer treatment. Under Sabzevari's leadership, PRECIGEN has made significant strides in advancing its pipeline of novel therapies. Her visionary approach and commitment to innovation have positioned the company as a leader in the field of precision medicine. Sabzevari's achievements extend beyond her corporate role; she is also an active member of the scientific community, frequently contributing to peer-reviewed journals and participating in industry conferences. Her dedication to improving patient outcomes through cutting-edge science continues to drive PRECIGEN's mission forward.